Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 89 of 116

  1. C2321001

    Pfizer Australia Pty Ltd

    Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 1 other active

    1 trial

  2. C2321006

    Pfizer Australia Pty Ltd

    Small cell lung cancer, Castration-resistant prostate cancer, Follicular lymphoma

    phase 1 other active

    1 trial

  3. C2321007

    Pfizer Australia Pty Ltd

    small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), follicular lymphoma (FL)

    phase 1 other active

    1 trial

  4. C4161006

    Pfizer Australia Pty Ltd

    (HR) -positive human epidermal growth factor receptor 2 (HER2) -negative breast cancer (BC), non-small cell lung cancer (NSCLC), ovarian cancer, and triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  5. C4391010

    Pfizer Australia Pty Ltd

    metastatic/advanced breast cancer

    phase 1 other active

    1 trial

  6. C4551007

    Pfizer Australia Pty Ltd

    locally advanced or metastatic ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  7. C4551010

    Pfizer Australia Pty Ltd

    locally advanced or metastatic HR+/HER2- breast cancer

    phase 1 other active

    1 trial

  8. C4891037

    Pfizer Australia Pty Ltd

    ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  9. C4891038

    Pfizer Australia Pty Ltd

    ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  10. C5911001 - SGN-CD25V

    Pfizer Australia Pty Ltd

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    phase 1 other active

    1 trial

  11. C5951001

    Pfizer Australia Pty Ltd

    advanced solid tumors

    phase 1 other active

    1 trial

  12. C6001001

    Pfizer Australia Pty Ltd

    Non-muscle invasive bladder cancer (NMIBC)

    phase 1 other active

    1 trial

  13. C6081001

    Pfizer Australia Pty Ltd

    KRAS mutated advanced solid tumors

    phase 1 other active

    1 trial

  14. CA011-1010

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  15. CA059-001

    Celgene Europe Limited

    Acute Myeloid Leukemia and Myelodysplastic Syndromes

    phase 1 other active

    1 trial

  16. CA111-001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  17. CA127-1027

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  18. CA177-1036

    Turn Therapeutics

    Phase 1: Advanced solid tumors harboring genetic alterations in MET

    phase 1 other active

    1 trial

  19. CA235-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  20. CA240-0008

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  21. CA243-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  22. CAAA617A12101

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  23. CADPT01C12101

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  24. CAN-2409 + valacyclovir

    Candel Therapeutics

    Lung Cancer

    phase 1 mab completed

    1 trial

  25. CAR T cells

    Qian Wenbin

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  26. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  27. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  28. CAR-T Therapy

    Zhao Weili

    Peripheral T Cell Lymphoma

    phase 1 small molecule active

    1 trial

  29. CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Relapsed Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  30. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  31. CAR-T cells chimenric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  32. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  33. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  34. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  35. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  36. CB-010

    Caribou Biosciences

    Lymphoma, Non-Hodgkin

    phase 1 gene therapy active

    1 trial

  37. CB-012

    Caribou Biosciences

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule terminated

    1 trial

  38. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  39. CC-122

    Bristol-Myers Squibb

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  40. CC-486

    Celgene Europe Limited

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  41. CC-90010-GBM-002

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  42. CC-90010-ST-001

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  43. CC-90011-SCLC-001

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  44. CCT3833

    United Therapeutics Europe Ltd

    Melanoma

    phase 1 small molecule completed

    1 trial

  45. CD-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  46. CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

    United Therapeutics Europe Ltd

    HER2 Negative Breast Carcinoma

    phase 1 mab active

    1 trial

  47. CD19-CD22 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  48. CD19-TriCAR-T/SILK

    Biotech Pharmaceutical Co.,

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.